Selective bladder conservation using transurethral resection, chemotherapy, and radiation: Management and consequences of TA, T1, and TIS recurrence within the retained bladder

Urology

Volumn 58, Issue 3, 2001, Pages 380-385

  Zietman, A L ^a   Grocela, J ^a   Zehr, E ^a   Kaufman, D S ^a   Young, R H ^a   Althausen, A F ^a   Heney, N M ^a   Shipley, W U ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER RISK; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTINEOPLASTIC PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYSTECTOMY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, CONFORMAL; SALVAGE THERAPY; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0034874086     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01219-5     Document Type: Article

References (17)

1. Organ-conserving approaches to muscle-invading bladder cancer; alternatives to the radical cystectomy in the new century
2. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy
3. Concomitant 5-fluouracil-cisplatin and bifractionated split course radiation therapy for invasive bladder cancer
4. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder; a prospective study
5. Efficacy of radiochemotherapy with platin derivatives compared to radiotherapy alone in organ-sparing treatment of bladder cancer
6. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy; initial results of RTOG 89-03
7. Neoadjuvant chemotherapy for invasive bladder cancer; prognostic factors for survival in patients treated with MVAC with 5-year follow-up
8. The current status of bladder preservation in the treatment of muscle invasive bladder cancer
9. Bladder-sparing strategies for transitional cell carcinoma
10. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluouracil, and twice daily radiation followed by selective bladder preservation in operable patients with muscle-invading bladder cancer
11. Initial results of RTOG 95-06; a phase I/II trial of transurethral surgery and fractionated twice-daily radiation with concurrent cisplatin and 5-fluouracil followed by either selective bladder preservation or cystectomy for patients with muscle-invading bladder cancer
12. Intravesical bacillus Calmette-Guérin or mitomycin C in the treatment of carcinoma of the bladder following prior pelvic radiation therapy
13. Carcinoma in situ
14. Tumor progression and survival of patients with high grade, non-invasive papillary bladder tumors; 15 year outcome
15. Low dose bacillus Calmette-Guérin for carcinoma in situ of the bladder; long-term results
16. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy